-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing Omega Therapeutics (NASDAQ:OMGA) and ERYTECH Pharma (NASDAQ:ERYP)
Reviewing Omega Therapeutics (NASDAQ:OMGA) and ERYTECH Pharma (NASDAQ:ERYP)
ERYTECH Pharma (NASDAQ:ERYP – Get Rating) and Omega Therapeutics (NASDAQ:OMGA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.
Insider and Institutional Ownership
4.9% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 88.8% of Omega Therapeutics shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by insiders. Comparatively, 60.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Get ERYTECH Pharma alerts:Profitability
This table compares ERYTECH Pharma and Omega Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
ERYTECH Pharma | N/A | N/A | N/A |
Omega Therapeutics | N/A | -44.99% | -38.54% |
Valuation and Earnings
This table compares ERYTECH Pharma and Omega Therapeutics' top-line revenue, earnings per share (EPS) and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ERYTECH Pharma | $4.95 million | 5.39 | -$63.65 million | N/A | N/A |
Omega Therapeutics | $140,000.00 | 1,678.27 | -$68.28 million | ($1.97) | -2.49 |
ERYTECH Pharma has higher revenue and earnings than Omega Therapeutics.
Analyst Ratings
This is a summary of current ratings and price targets for ERYTECH Pharma and Omega Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ERYTECH Pharma | 0 | 3 | 0 | 0 | 2.00 |
Omega Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Omega Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 22.20%. Given Omega Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Omega Therapeutics is more favorable than ERYTECH Pharma.
Summary
Omega Therapeutics beats ERYTECH Pharma on 6 of the 10 factors compared between the two stocks.
About ERYTECH Pharma
(Get Rating)
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
About Omega Therapeutics
(Get Rating)
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for ERYTECH Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ERYTECH Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
ERYTECH Pharma (NASDAQ:ERYP – Get Rating) and Omega Therapeutics (NASDAQ:OMGA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.
纳斯达克:ERYP-GET评级)和欧米茄治疗(纳斯达克:OMGA-GET评级)都是小盘医疗公司,但哪种投资更好?我们将根据这两家公司的股息、收益、风险、机构所有权、盈利能力、分析师建议和估值的强弱对它们进行比较。
Insider and Institutional Ownership
内部人与机构持股
4.9% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 88.8% of Omega Therapeutics shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by insiders. Comparatively, 60.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Erytech Pharma 4.9%的股份由机构投资者持有。相比之下,欧米茄治疗公司88.8%的股份由机构投资者持有。Erytech Pharma 1.9%的股份由内部人士持有。相比之下,欧米茄治疗公司60.0%的股份由内部人士持有。强大的机构持股表明,对冲基金、大型基金管理公司和捐赠基金相信,一家公司的长期表现将好于大盘。
Profitability
盈利能力
This table compares ERYTECH Pharma and Omega Therapeutics' net margins, return on equity and return on assets.
下表比较了Erytech Pharma和Omega治疗公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
ERYTECH Pharma | N/A | N/A | N/A |
Omega Therapeutics | N/A | -44.99% | -38.54% |
净利润率 | 股本回报率 | 资产回报率 | |
Erytech制药公司 | 不适用 | 不适用 | 不适用 |
欧米茄治疗公司 | 不适用 | -44.99% | -38.54% |
Valuation and Earnings
估值和收益
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ERYTECH Pharma | $4.95 million | 5.39 | -$63.65 million | N/A | N/A |
Omega Therapeutics | $140,000.00 | 1,678.27 | -$68.28 million | ($1.97) | -2.49 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
Erytech制药公司 | 495万美元 | 5.39 | -6,365万元 | 不适用 | 不适用 |
欧米茄治疗公司 | $140,000.00 | 1,678.27 | -6,828万元 | ($1.97) | -2.49 |
ERYTECH Pharma has higher revenue and earnings than Omega Therapeutics.
Erytech Pharma的收入和收益比Omega治疗公司高。
Analyst Ratings
分析师评级
This is a summary of current ratings and price targets for ERYTECH Pharma and Omega Therapeutics, as provided by MarketBeat.
这是MarketBeat提供的Erytech Pharma和Omega治疗公司的当前评级和目标价摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ERYTECH Pharma | 0 | 3 | 0 | 0 | 2.00 |
Omega Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
Erytech制药公司 | 0 | 3 | 0 | 0 | 2.00 |
欧米茄治疗公司 | 0 | 1 | 1 | 0 | 2.50 |
Omega Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 22.20%. Given Omega Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Omega Therapeutics is more favorable than ERYTECH Pharma.
欧米茄治疗公司的共识目标价为6.00美元,暗示潜在上涨22.20%。鉴于欧米茄治疗公司更高的共识评级和更高的可能上行空间,分析师们显然认为欧米茄治疗公司比Erytech Pharma更有利。
Summary
摘要
Omega Therapeutics beats ERYTECH Pharma on 6 of the 10 factors compared between the two stocks.
欧米茄治疗公司在两只股票比较的10个因素中有6个超过了Erytech Pharma。
About ERYTECH Pharma
关于Erytech Pharma
(Get Rating)
(获取评级)
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Erytech Pharma S.A.是一家临床阶段的生物制药公司,在法国和美国开发基于红细胞的癌症和孤儿疾病疗法。它的主要候选产品是eryaspase,它正处于临床开发的第三阶段,用于治疗二线胰腺癌,并处于第二阶段,用于治疗三阴性乳腺癌和二线急性淋巴细胞白血病患者。该公司还致力于开发丹甲硫酶,这是一种临床前候选产品,由红细胞中的甲硫氨酸裂解酶组成,用于靶向蛋氨酸癌症。该公司成立于2004年,总部设在法国里昂。
About Omega Therapeutics
关于欧米茄治疗公司
(Get Rating)
(获取评级)
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
欧米茄治疗公司是一家处于发展阶段的生物制药公司。其omega表观基因组编程平台旨在通过利用表观遗传学的力量来配合自然的操作系统,表观遗传学是基因控制和细胞分化的机制。该公司正在开发omega表观基因组控制器(OEC)候选基因,以上调HNF4a的表达,HNF4a是一种转录主调控因子,作为恢复慢性肝病患者肝细胞功能的潜在途径;控制与糖尿病和其他疾病患者的细胞生长抑制密切相关的基因的表达,以恢复角膜再生的能力;下调CXCL1、2、3和IL-8基因簇的表达;控制特发性肺纤维化患者的相关基因的表达,以阻止或逆转疾病进展并改善疾病预后;下调SFRP1的表达,一种抑制头发生长的蛋白质;治疗非小细胞肺癌和小细胞肺癌。它还在开发OTX-2002,以下调癌基因c-Myc的表达。该公司成立于2016年,总部位于马萨诸塞州剑桥市。
Receive News & Ratings for ERYTECH Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ERYTECH Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
获得Erytech Pharma Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Erytech Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧